David Platt
Chief Executive Officer bei BIOXYTRAN, INC.
Vermögen: 7 Mio $ am 31.03.2024
Profil
David Platt is the founder of Galectin Therapeutics, Inc. (founded in 2001), SafeScience, Inc. (founded in 1995), International Gene Group, Inc. (founded in 1992), Boston Therapeutics, Inc. (founded in 2010), and Oxygen Therapy, Inc. (founded in 2016).
He holds the titles of Chairman, President & Chief Executive Officer at Galectin Therapeutics, Inc. from 2001 to 2009, Chairman & Chief Executive Officer at SafeScience, Inc. in 2000, Chairman & Chief Executive Officer at International Gene Group, Inc. from 1992 to 2000, Director at Boston Therapeutics, Inc. in 2017, and was previously the President at Oxygen Therapy, Inc. since 2016.
Dr. Platt's current job is Chairman & Chief Executive Officer at BioXyTran, Inc. since 2018.
He has also held former positions as Chairman, President & Chief Executive Officer at U.S.
Rare Earth Minerals, Inc., Chairman, President, CEO, CFO & Treasurer at Avanyx Therapeutics, Inc., and Chairman & Chief Executive Officer at BioXyTran, Inc. Additionally, Dr. Platt worked as a Research Scientist-Internal Medicine at the University of Michigan from 1991 to 1992.
He obtained a doctorate degree from The Hebrew University of Jerusalem in 1988.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
BIOXYTRAN, INC.
38,78% | 27.03.2024 | 64 571 592 ( 38,78% ) | 7 Mio $ | 31.03.2024 |
Aktive Positionen von David Platt
| Unternehmen | Position | Beginn |
|---|---|---|
| BIOXYTRAN, INC. | Chief Executive Officer | 01.03.2018 |
Oxygen Therapy, Inc.
 Oxygen Therapy, Inc. Pharmaceuticals: MajorHealth Technology Oxygen Therapy, Inc. is an early stage pharmaceutical company, which engages in the development, manufacture, and commercialization of an innovative platform of oxygen therapeutic treatments for hypoxic conditions and necrosis prevention. Its product pipeline includes OTI-629, an anti-necrosis drug; and OTI-1011, a resuscitative agent for wound healing applications. The company was founded by David Platt on May 20, 2016 and is headquartered Newton, MA. | Founder | 20.05.2016 |
Ehemalige bekannte Positionen von David Platt
| Unternehmen | Position | Ende |
|---|---|---|
| NANOMIX CORPORATION | Founder | 08.06.2017 |
Avanyx Therapeutics, Inc.
 Avanyx Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Avanyx Therapeutics, Inc. engages in the development, manufacture and marketing of therapeutic drugs with a focus on glyco-pathology, a specialized field involving understanding the importance of Glycoproteins in biochemistry and progression of diseases. The company is headquartered in Newton, MA | Chief Executive Officer | 30.11.2010 |
| GALECTIN THERAPEUTICS INC. | Chief Executive Officer | 12.02.2009 |
| SafeScience, Inc. | Chief Executive Officer | 01.01.2000 |
| International Gene Group, Inc. | Chief Executive Officer | 01.01.2000 |
Ausbildung von David Platt
| The Hebrew University of Jerusalem | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| GALECTIN THERAPEUTICS INC. | Health Technology |
| Private Unternehmen | 8 |
|---|---|
U.S. Rare Earth Minerals, Inc.
 U.S. Rare Earth Minerals, Inc. Other Metals/MineralsNon-Energy Minerals U.S. Rare Earth Minerals, Inc. focuses on the sale and distribution of products derived from its mining activities relating to natural mineral deposits, commonly known as Calcium Montmorillonite. These activities are carried out through a web-based and distributor-based sales program directed at agricultural, animal and human uses of the product. It markets and sells the product extracted in the mining process under the name EXCELERITE. The company was founded on June 9, 2008 and is headquartered in Panaca, NV. | Non-Energy Minerals |
Avanyx Therapeutics, Inc.
Avanyx Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Avanyx Therapeutics, Inc. engages in the development, manufacture and marketing of therapeutic drugs with a focus on glyco-pathology, a specialized field involving understanding the importance of Glycoproteins in biochemistry and progression of diseases. The company is headquartered in Newton, MA | Health Technology |
| SafeScience, Inc. | |
| International Gene Group, Inc. | |
Boston Therapeutics, Inc.
 Boston Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Boston Therapeutics, Inc. is a pharmaceutical company, which engages in the development, manufacture, and commercialization of novel compounds based on complex carbohydrate chemistry. Its products are designed to help manage blood sugar, treat pre-diabetes, and diabetes related pathologies. Its drug candidates comprises of BTI320, BTI-410, and IPOXYN. The company was founded by David Platt and Kenneth A. Tassey Jr. on August 24, 2009 and is headquartered in Lawrence, MA. | Health Technology |
Oxygen Therapy, Inc.
Oxygen Therapy, Inc. Pharmaceuticals: MajorHealth Technology Oxygen Therapy, Inc. is an early stage pharmaceutical company, which engages in the development, manufacture, and commercialization of an innovative platform of oxygen therapeutic treatments for hypoxic conditions and necrosis prevention. Its product pipeline includes OTI-629, an anti-necrosis drug; and OTI-1011, a resuscitative agent for wound healing applications. The company was founded by David Platt on May 20, 2016 and is headquartered Newton, MA. | Health Technology |
BioXyTran, Inc. /Old/
 BioXyTran, Inc. /Old/ Pharmaceuticals: MajorHealth Technology BioXyTran, Inc. operates as a biopharmaceutical company. The firm focuses on the development and commercialization of treatments to prevent catastrophic brain damage resulting from hypoxic conditions following brain stroke. The company was founded in 2017 and is headquartered in Newton, MA. | Health Technology |
| BioXyTran, Inc. |
